Still River inks patent license deal with MIT

Proton radiotherapy developer Still River Systems has signed a long-term licensing agreement with the Massachusetts Institute of Technology (MIT).

Still River will utilize superconducting accelerator technologies that were developed at MIT's Plasma Science and Fusion Center in collaboration with the firm. The company said it would make use of these technologies in conjunction with its own developments for its Monarch²⁵⁰ single-room proton therapy platform.

The first Monarch²⁵⁰ is currently being installed at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis.